JP Morgan analyst Amyn Pirani initiates coverage on Tata Motors (NYSE:TTM) with a Overweight rating.
Allogene’s BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma
The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc’s (NASDAQ:ALLO) ALLO-715 to treat multiple myeloma. In April 2021, ALLO-715 received…